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Melanomas and nevi share many of the same growth-promoting mutations. However, melanomas grow relentlessly while benign
nevi eventually undergo growth arrest and stabilize. The diﬀerence in their long-term growth potential may be attributed to
activation of cellular senescence pathways. The primary mediator of senescence in nevi appears to be p16. Redundant, secondary
senescencesystemsarealsopresentandincludethep14-p53-p21pathway,theIGFBP7pathway,theFBXO31pathway,andthePI3K
mediated stress induced endoplasmic reticulum unfolded protein response. It is evident that these senescence pathways result in
an irreversible arrest in most instances; however, they can clearly be overcome in melanoma. Circumvention of these pathways is
most frequently associated with gene deletion or transcriptional repression. Reactivation of senescence mechanismscould serve to
inhibit melanoma tumor progression.
1.Introduction
Melanocytic neoplasms represent a diverse group of tumors
that can be either benign (nevi) or malignant (melanoma).
The most striking diﬀerence between benign and malignant
melanocytic neoplasms is that the former eventuallystabilize
and undergo cellular senescence while the latter continue to
grow. It is evident that cellular senescence, loosely deﬁned
as an arrested proliferative capacity, is governed by multiple
mechanisms. It is becoming clear that these mechanisms
represent the cellular processes that diﬀerentiate nevi from
melanomas. In this paper, the conceptual framework for
nevus growth will be reviewed along with what is known
about cellular senescence pathways that terminate nevus
growth.
2.NevusLifeCycle
Itishypothesizedthatnevioriginatesecondarytoamutation
sustained in a single progenitor cell [1]. This mutation then
induces the progenitor cell to develop into a nevus that
follows an archetypal life cycle. The stages of this cellular
life cycle can be separated into the phases of initiation,
promotion, growth termination, and involution [1].
Initiation occurs when the nevus progenitor cell acquires
a mutation. The mutated cell then remains quiescent and
inconspicuous. Promotion occurs when the mutated cell
is stimulated to undergo proliferation. This unmasks the
mutation, which in turn causes melanocytic nevus cells to
accumulate. It is not known exactly what drives this process.
However, it is signiﬁcant that the majority of nevi develop
in late childhood and young adulthood. Presumably, the
endogenous factors that promote maturation of the child
into an adult also promote the growth of nevi. Some insight
into this process may be gleaned from the study of eruptive
nevi wherein immunomodulatory agents and cytokines are
thought to promote their growth.
Growth termination begins to occur as the nevi mature.
A number of molecular pathways are involved in growth
termination and current knowledge will be reviewed in
more detail below. Involution occurs when the growth-
arrested nevus begins to regress and eventually disappears.
This may occur through a number of processes including
apoptosis, immune destruction, or withdrawal of growth2 ISRN Dermatology
factors like MSH [2–4]. It is interesting to note that while
late childhood and young adulthood represents the time
period in which the majority of nevus promotion occurs,
it is also the time period in which most nevi begin to
involute [5] .T h u s ,i ti sp o s s i b l et h a tn e v is t i l lp r e s e n ti nl a t e
adulthood represent nevi that possess cellular mechanisms
that make them resistant to involution. It remains impor-
tant to understand these mechanisms in order to develop
strategies to block growth, induce senescence, and promote
involution.
3.Deﬁning Senescence
Senescence is said to occur when a cell exits the cell cycle
and stops proliferating. In melanocytes, this growth arrest is
accompanied by a number of morphological and functional
changes. These changes include adoption of a large, ﬂat,
sometimes vacuolated appearance, alterations in chromatin
structure, diﬀerential gene expression patterns, and produc-
tion of senescence-associated-beta-galactosidase (SA-β-Gal)
[6–10]. Of note, alternations in growth media conditions,
molecular mutations, and knock out models have been
shown to allow cells to either partially or completely over-
come senescence.
The basic question remains: what is senescence and is it
really permanent? Nonproliferating cells capable of readily
exiting and reentering the cell cycle are often referred to
as quiescent. Consequently, it is necessary to diﬀerentiate
senescence from quiescence. Many would argue that the
major diﬀerencebetweenquiescentandsenescentcellsisthat
the former will proliferate in response to a mitogenic signal
while the latter will not [11, 12]. This occurs because the
phenomenon of quiescence is associated with reversible epi-
genetic silencing of transcription through reversible histone
modiﬁcation [13].
Furthermore, it has been argued that the discovery of
“irreversible” transcriptional silencing through the develop-
ment of senescence associated heterochromatin foci (SAHF)
[14] distinguishes a senescent cell from a quiescent cell.
While it is true that SAHF is a salient feature of senescent
cells and that it more readily prohibits transcription than
the histone modiﬁcations present in quiescent cells, the
irreversibility of SAHF has been questioned [15]. This
suggests that there are either more complex mechanisms
permanently keeping cells from proliferating or that senes-
cence is reversible, just to an exponentially lesser extent than
quiescence.
4.TelomeresandNevus Senescence
It is well accepted that telomeres in somatic cells undergo
shortening with each successive cellular division. This pro-
gressive reduction in size culminates in growth arrest. It
has also been shown that the enzyme telomerase functions
to extend telomeres, thus permitting continuous cellular
divisions [17]. Subsequently, it was shown that telomerase
activity is increased in germ cells and immortal cancer cell
lines [18]. This occurs because these cells express telomerase
reverse transcriptase (hTERT), the catalytic subunit of te-
lomerase that is absent in somatic cells.
Telomere shortening is known to promote melanocyte
senescence [19]. It has also been shown that melanocytes
supplemented with hTERT can escape normal senescence
[19]. Therefore, it is not surprising that benign nevi demon-
strate no telomerase activity while over 90% of melanomas
do [20]. This suggests that once melanocytes within nevi
undergo a certain number of divisions, their telomeres
will reach a critical size that induces growth arrest and
senescence.
It is also interesting to note that there is a strong cor-
relation between nevus count, nevus size, and systemic
telomere length [21]. This suggests that melanocytic cells in
individuals with long telomeres are able to undergo a greater
number of cell divisions before their telomeres shrink to
the critical size that induces senescence. This in turn not
only allows more nevi to develop but also permits them to
reach larger diameters before undergoing senescence [21].
Consequently, telomere shortening appears to represent one
mechanism that signals growing melanocytes within nevi to
exit the cell cycle and undergo senescence.
5.Molecular Mediators of Telomere-Dependent
CellularSenescence
Most of our knowledge pertaining to molecular senes-
cence initially was derived from the study of mouse and
human ﬁbroblasts. Althoughhuman melanocytic senescence
pathways deviate from these more traditional models, a
brief review of their function is useful in understanding
melanocyte senescence. Fibroblasts were initially thought to
possess two distinct phases of senescence known as mortality
phase 1 (M1) and mortality phase 2 (M2). Each of these
phasesisregulated bymolecularpathwaysandcellularevents
that prevent cells from undergoing cell cycle progression.
This ﬁrst phase, M1, is mediated by two major molecular
pathways: the p53-p21 pathway (Figure 1(a)) and the p16-
Rb pathway (Figure 1(b)). It was previously proposed that
telomere shortening is responsible for induction of both of
these pathways [22]. While this proved to be true, there
existssomevariationinpathwayactivation.Itiswellaccepted
that telomere shortening results in an upregulation of both
p53 and p21 [23, 24]. There also exists ample evidence that
shows p16 is upregulated in response to telomere shortening
[25–27]. However, telomere-induced p16 expression occurs
with delayed kinetics. Thus, it is apparent that telomere
shortening is not the primary mechanism responsible for
p16-Rb-mediated senescence. Consequently, p16-Rb has
occasionally beenreferredtoasthemediatorofthetelomere-
independent pathway of senescence, despite the fact that it
can be induced by telomere shortening [28]. Nevertheless,
only one of these pathways is necessary to keep ﬁbroblasts
senescent in M1 [29]. Consequently, both pathways must be
knocked out to allow cells to escape M1 senescence.
In the event that both of these pathways are inactivated,
ﬁbroblasts are able to overcome the ﬁrst phase of senescence
and continue to replicate for a ﬁnite number of divisions.ISRN Dermatology 3
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Figure 1: The p14-p53-p21 pathway and the p16-Rb signaling pathways involved in ﬁbroblast senescence. (a) Activated p53 induces
expression of p21. The protein p21 binds to cyclin-dependent kinase2 (CDK2), which in turn impedes CDK2 from complexing with Cyclin
EandCyclinA. SincetheCDK2-Cyclin E/Acomplexesarerequired forDNA replicationto begin, p21eﬀectively stopscell replication.Mdm2
is a strongantagonistofp53. It notonlyprevents production ofnew p53 through transcriptional inhibition,but alsoexports active p53 from
the nucleus and targets it for proteolytic destruction through ubiquitination. The tumor suppressor protein p14 works to upregulate p53
by inhibiting Mdmd2 [16]. (b) While in its unphosphorylated state, Rb sequesters the transcription factor (E2F) responsible for initiating
DNA replication. Unphosphorylated Rb also induces the formation of SAHF, which prevents free E2F from complexing with DNA. When
cyclin-dependent kinase4 (CDK4) complexes with cyclin D, it is able to phosphorylate Rb, thus releasing E2F and allowingDNA replication
to occur. The protein p16 works as a tumor suppressor by preventing CDK4 from complexing with cyclin D.
At this point, the cells enter the second phase of senescence,
M2. This is often referred to as “crisis.” This second phase
of senescence occurs because the telomeres have become
so short that they are no longer able to prevent end to
end fusions of chromosomes. These fusions result in dicen-
tromeric chromosomes that undergo an increased incidence
ofdoublestrandedDNAbreaks.Inturn,thesebreaksprevent
further cellular divisions.
6.Mitogen- and Oncogene-InducedSenescence
It has become readily apparent that there exists another
phase of senescence that occurs before M1. This phase
of senescence, ﬁrst referred to as M0, is thought to be
largely dependent on the p16-Rb pathway [30]a n do c c u r s
independently of telomere shortening [31]. Other molecular
mediators, such as p14 and p53, have also been implicated
in M0 [32]. Recently, it has been shown that neither phar-
macologic inhibition of DNA damage nor direct antagonism
of p53 aﬀects M0 senescence in nevi [33]. Furthermore,
disruption of the p16 pathway in M0 arrested keratinocytes
resulted in the recommencement of cellular division for
a ﬁnite number of cycles that eventually underwent p53
mediated M1 senescence. Consequently, it appears that the
p16-Rb pathway is the primary mediator of M0 senescence.
This phase of senescence is now known to be induced by
overstimulationofmitogenicpathways[34].Thissenescence
phenomenon is now referred to as a telomere-independent
mitogenic clock that can be abrogated by certain growth
conditions [35] or induced by oncogenic signaling [36].
7.Molecular Melanocyte Senescence
Nevi often possess oncogenic mutations in proteins that
participate in mitogenic signaling [1]. Consequently, it is
not surprising to ﬁnd that nevi undergo M0 mitogenic
senescence. Michaloglou et al. conﬁrmed this in vivo by
demonstrating that BRAF V600E mutant-positive nevi have
increased p16 and SA-β-Gal expression [37]. Furthermore,
these nevi had an increased number of SAHF and did not
possess critically shortened telomeres. Taken together, this
evidenceconﬁrmsthatneviundergoatelomere-independent
p16-mediated mitogenic senescence when the BRAF V600E
mutation is present.
However, Michaloglou et al. also demonstrated that
islands of senescent melanocytes within the BRAF V600E
nevi did not have high expression patterns of p16. One
explanation forheterogeneousexpression ofp16insenescent
nevi involves the observation that not all melanocytes within
V600E mutant-positive nevi possess the mutation [38].
Consequently, the islands of cells not expressing p16 may
not have contained the V600E BRAF mutation. However,
another study demonstrated that p16 induction is not
required for BRAF V600E-mediated senescence to occur
[39]. It is thusmost likelythat othermolecular mediators are
also involved in BRAF V600E-induced senescence.4 ISRN Dermatology
Other studies have shown that BRAF V600E mutations
induce senescence through upregulation of insulin-like
growth factor-binding protein 7 (IGFBP7) [40]. IGFBP7
works to inhibit mitogenic RAF-MEK-ERK signaling
through autocrine and paracrine stimulation. Consequently,
it is not surprising to ﬁnd that only 23% of BRAF V600E-
positive nevi have detectable levels of ERK, while 93% of
BRAF V600E-positive melanomas have detectable levels of
ERK [41]. It is thus possible that the IGFBP7 pathway is lost
in melanoma and that this could contribute to overcoming
senescence.
The cellular response to DNA damage induced by hyper-
replicationofcells exposedtomitogenicoverstimulationalso
plays a role in mediating senescence [42, 43]. This has been
shown to occur through destruction of Cyclin D1 by the
FBXO31 protein in BRAF V600E-positive melanocytes [44].
So while the p16 pathway may play a signiﬁcant role in
BRAF-induced senescence, it is clear that other mechanisms
exist. Consequently, p16 may not be necessary for BRAF-
induced senescence.
HRAS-induced senescence exhibits a number of mark-
edly distinct characteristics when compared to BRAF-in-
duced senescence. For example, HRAS mutations induce
senescence more rapidly than BRAF mutations in human
melanocytes [45]. Additionally, it has been demonstrated
that melanocytes that undergo HRAS-induced senescence
display speciﬁc microscopic features, like extensive vac-
uolization, a ﬁnding not known to occur in BRAF-induced
senescence. Further investigation of this phenomenon
demonstrated that these features are secondary to a PI3K
pathway mediated stress induced endoplasmic reticulum
unfolded protein response [45]. Thus, it is not surprising
that there is a phenotypic variation in HRAS and BRAF
senescence phenotypes given the fact that HRAS is upstream
of PI3K, while BRAF is not. At ﬁrst glance, it is a little more
surprising that NRAS-induced senescence (NRAS is an iso-
form of HRAS that is able to activate identical downstream
eﬀectors) does not display the HRAS-induced senescence
phenotype. However, this ﬁnding is readily explained by the
fact that HRAS has a much greater aﬃnity for PI3K [46].
Despite the fact that HRAS can induce a phenotypically
distinct form of senescence, it appears that HRAS-positive
nevi are still governed by more traditional modes of senes-
cence.Forexample, it has been shown thattheloss of thep16
locus prevents telomere-induced senescence in melanocytes
with HRAS mutations [47]. Similar ﬁndings have been
demonstrated in human ﬁbroblasts with HRAS mutations
[28]. The occurrence of p16-induced senescence and the
unfolded protein response in HRAS mutant nevi supports
the notion that there are multiple pathways and mediators
that serve as repetitive safeguards against unchecked prolif-
eration.
It is not unreasonable to put forth the notion that the
NRAS-induced senescence phenotype may be considered a
hybrid of BRAF and HRAS-induced senescence phenotypes.
This is because while NRAS-induced senescence occurs with
similar timing as BRAF-induced senescence, it displays a
mild form of vacuolization [45]. These ﬁndings are likely
secondary to RAS isoform speciﬁcity, with NRAS generating
greater amounts of phosphorylated ERK and HRAS prefer-
entially activating the PI3K pathway [45, 46].
There are a number of other important lessons that have
been learned from melanocytes harboring NRAS mutations.
For example, it has been shown that NRAS-induced senes-
cence is associated with DNA damage that is postulated to
upregulate both p16-Rb and p14-p53-p21 [33]. Haferkamp
et al. also conﬁrmed that while the p16-Rb pathway appears
to be the more prominent mediator of senescence in
melanocytes, the p53 pathway is capable of initiating a
phenotypically identical, though delayed,form of senescence
[33]. One of the most interesting ﬁndings was that while
p16 is by no means required to induce senescence in NRAS
mutant melanocytes [48], it was necessary to form SAHF
[33]. Consequently, the possibility exists that melanocytes
with defective p16-Rb cellular machinery may undergo
incomplete, pathological forms of senescence that are more
prone to melanomagenesis.
It has also been shown the potency of mitogenic pathway
stimulation has an inﬂuentialrole in determiningif a cellwill
senesce. Leikam et al. demonstrated that strong oncogenic
signaling led to the development of a senescent multinu-
cleated melanocyte population in vitro while weak signaling
promoted proliferation [49]. Reactive oxygen species, pre-
viously known to be induced by the RAS-RAF-MEK-ERK
pathway[50],wereshowntoberesponsibleforthissenescent
phenotype independent of p53 and Rb transcription levels.
The authors also noted that the presence of this multinu-
cleated phenotype precludes this form of senescence from
occurring through G0 exit from the cell cycle commonly
seen in M1. This is because the presence of multiple
nuclei suggests that the cell has already passed the DNA
synthesis checkpointas itis actively replicating itsDNA.This
may explain the lack of correlation between this senescent
phenotype and p53 and Rb expression. Consequently, the
presence of multinucleated melanocytes in nevi may be
evidence of yet another, non-G0 senescence mechanism
meant to protect cells against overactive mitogenic signaling.
8.Breaking Senescence
It is evident that there exist multiple mechanisms through
which nevi initiate senescence (Figure 2). This includes
telomere shortening, mitogenic overstimulation, increased
free radical production, and DNA damage. These stimuli
trigger senescence through multiple, often shared molecular
mechanisms that include induction of the p16-Rb path-
way, the p14-p53-p21 pathway, the IGFBP7 pathway, the
FBXO31 pathway, and the endoplasmic reticular unfolded
protein response. The redundancy of these mechanisms
likely evolved as a safeguard against tumor initiation. Given
this redundancy, it is a little surprising that disruption of
a single component of these pathways can both promote
nevus formation and confer such a markedly increased risk
of developing melanoma.
Despite the fact that p16 and p14 share no protein
sequence similarity, they are both encoded by a single
gene locus known as cyclin-dependent kinase inhibitor 2AISRN Dermatology 5
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Figure 2: Overview of senescence pathways. Stimuli and cellular mechanisms responsible for the various stages of senescence. Each phaseof
senescencepreventscells fromundergoingfurther cell division.M0canoccur throughmultiplemechanisms,andtherelative contributionof
each is a function of the factors driving mitogenic stimulation (e.g., BRAF versus HRAS mutation). M0 appears to be driven predominantly
by the p16/Rb pathway in melanoma. a: Unfolded protein response (unique to HRAS mutant-positive cells).
(CDKN2A) [51]. Mutations in this gene locus have been
reported that can aﬀect p16, p14, or both p16 and p14 [52].
The subsequent discussion refers to mutations that only
aﬀect one of these two proteins.
Individuals with systemic deactivating p16 mutations
have been shown to possess a greater number of nevi [53].
They also continue to develop new nevi at a much faster rate
than wild type p16 familial controls [54]. These ﬁndings are
supportedbyareport ofapedigreeharboring aheatsensitive
deactivating mutation in p16 that developed a signiﬁcantly
larger number of nevi in sun exposed areas [55]. It is likely
that melanocytes in these individuals fail to undergo M0
and continue to divide until their telomeres shorten to a
point that M1 is initiated. Given the above, it is clear that
disruption of the p16 pathway is suﬃc i e n tt oh i n d e ro re v e n
prevent senescence in melanocytes.
Nevi have been shown to express signiﬁcantly more p16
than melanomas [56]. Straume et al. reported that 45%
of primary melanomas and 77% of metastatic melanomas
lacked expression of p16 [57]. Although this demonstrates
that compromised p16 function is a predisposing factor for
developing melanoma, it is not alone suﬃcient to initiate
melanomagenesis. Instead, it appears that loss of p16 may
be the transforming event that allows a benign nevus to
transform into a melanoma, thus overcoming senescence.
In such a model, loss of p16 expression could result in a
slow loss of SAHF, thus allowing strong mitogenic signaling
to eventually reactivate the cell cycle. While loss of p16
may be suﬃcient to allow continued nevus growth, multiple
mutations must occur within the senescence pathways to
induce melanomagenesis.
Mutations in other molecular mediators of senescence
like p14, p21, and p53 have been characterized in malignant
melanocytic neoplasms. Isolated p14 mutations occur less
frequently than p16 mutations [58, 59]. Like their p16
counterparts, individuals with a germline mutation aﬀecting
p14 are more susceptible to developing melanoma [60].
Though uncommon, it has been shown that p21 mutations
can also be present in melanoma [61]. Interestingly, p21 is
expressed with much greater frequency in melanomas (61%)
than in nevi (28%) [62]. This suggests that p21 acts more
as a failsafe mechanism designed to arrest cells that have
transformed and escaped p16-mediated senescence than as
a primary mediator of nevi senescence. Lastly, while p53
mutations have been described in melanoma, they occur
infrequently [63] and are thought to play only a minor
role in melanomagenesis [64]. However, recent evidence
suggests that p53 may play an active role in preventing nevus
progression to melanoma in the murine model [65]. Since
p19(themurineanalogueofp14)andp53haveaninherently
stronger rolein inducingsenescenceinmice thanin humans,
theimportance ofthispathwayinhumanmelanomaremains
unclear [66].
9.Conclusion
Senescence represents a dynamic, ongoing process with mul-
tiple stages and checkpoints that prevents cells from entering6 ISRN Dermatology
the cell cycle. As such, senescence acts as a barrier to uncon-
trolled tumor enlargement and malignant degeneration.
Senescence pathways are activated in benign nevi where they
work to prevent further growth. The p16 pathway appears
to be the primary mediator of senescence in nevi. It seems
that redundant, possibly secondary senescence systems are
also present innevi. These includethe p14-p53-p21pathway,
the IGFBP7 pathway, the FBXO31 pathway, and the PI3K
mediated stress induced endoplasmic reticulum unfolded
protein response. It is evident that though senescence results
in an irreversible arrest in most instances, it can clearly be
overcome in pathological processes, like melanoma. While
it is clear that these pathways are overcome with tumor
progression, the stage of melanomagenesis during which
the loss occurs is not known. However, the fact that most
melanomas appear to arise de novo suggests that some of
these pathways are overcome at very early stage. Continued
research in this area will also help us to better diﬀerentiate
benign and malignant tumors. It may also allow for the
development of senescence inducing therapies to hinder the
growth of melanoma cells.
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